[Immunological efficiency of DNA vaccine targeting dendritic cells against tumor].
OBJECTIVE
To construct the DNA vaccine containing ovalbumin (OVA) and Fc fusion gene targeting dentritic cells (DCs) and evaluate its anti-tumor efficiency in an E.G7-OVA-bearing tumor model.


METHODS
Constructed OVA-Fc-pcDNA3.1 plasmids were transfected into CHO cells with lipofectamine and the in vitro expression of OVA-Fc was determined by flow cytometry and ELISA. (51)Cr-relaese assay was used to determine the anti-tumor activity of cytotoxic T lymphocytes (CTLs) from splenocytes of immunized mice. According to tumor volume and survival time of the mice, the therapeutic effect of this vaccine was evaluated in E.G7-OVA-bearing tumor model.


RESULTS
DNA sequencing and restriction endonuclease digestion analysis indicated that the recombinant expression vector OVA-Fc-pcDNA3.1 had been constructed successfully. OVA-Fc expression could be detected in CHO cells transfected with OVA-Fc-pcDNA3.1 by ELISA and flow cytometry. The DNA vaccine containing OVA-Fc fusion gene inhibited tumor's growth and prolonged the time of tumor-bearing mice due to elicit the CTL-mediated anti-tumor immunity.


CONCLUSIONS
OVA-Fc-pcDNA3.1 DNA vaccine targeting dendritic cells can elicit the CTL-mediated anti-tumor immunity, which lays the foundation for further clinical experiments.
Zhu
Bo
B
Cancer Center of Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China. oncology_bozhu@yahoo.com.cn
Cheng
Xiao-ming
XM
Duan
Yu-zhong
YZ
Guo
Bo
B
Wu
Yu-zhang
YZ
Chen
Zheng-tang
ZT
D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D003713:Dendritic Cells / Q000187:drug effects* / Q000276:immunology; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D005434:Flow Cytometry; D005822:Genetic Vectors / Q000235:genetics; D051379:Mice; D008810:Mice, Inbred C57BL; D010047:Ovalbumin / Q000235:genetics / Q000276:immunology*; D010957:Plasmids / Q000235:genetics; D019444:Vaccines, DNA / Q000008:administration & dosage*; D023041:Xenograft Model Antitumor Assays
D019444:Vaccines, DNA; D010047:Ovalbumin